Technical Analysis for FLGT - Fulgent Genetics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 83.16 | 3.16% | 2.55 |
Earnings due: Nov 8
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Historical FLGT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | 3.16% | |
| Bullish Engulfing | Bullish | 3.16% | |
| Stochastic Reached Oversold | Weakness | 3.16% | |
| Multiple of Ten Bullish | Other | 3.16% | |
| Oversold Stochastic | Weakness | 3.16% | |
| Multiple of Ten Bearish | Other | 6.59% | |
| 20 DMA Resistance | Bearish | 5.71% | |
| Death Cross | Bearish | 5.71% | |
| 180 Bearish Setup | Bearish Swing Setup | 5.71% | |
| Multiple of Ten Bearish | Other | 5.71% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 3% | about 3 hours ago |
| Up 2% | about 3 hours ago |
| Rose Above Previous Day's High | about 3 hours ago |
| Rose Above 10 DMA | about 3 hours ago |
| Up 1% | about 3 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/08/2021
Fulgent Genetics, Inc. Description
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancers Genetics Medical Genetics Cardiovascular Disease Medical Tests Neurological Disorders Algorithms Molecular Diagnostics Vascular Diseases Cardiovascular Diseases Applied Genetics Urological Disorders Genetic Testing Adaptive Learning Qiagen Alternatives To Animal Testing
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 189.8899 |
| 52 Week Low | 30.05 |
| Average Volume | 522,535 |
| 200-Day Moving Average | 90.56 |
| 50-Day Moving Average | 89.07 |
| 20-Day Moving Average | 83.83 |
| 10-Day Moving Average | 80.76 |
| Average True Range | 4.63 |
| ADX | 11.49 |
| +DI | 19.16 |
| -DI | 26.15 |
| Chandelier Exit (Long, 3 ATRs) | 80.51 |
| Chandelier Exit (Short, 3 ATRs) | 89.56 |
| Upper Bollinger Bands | 92.42 |
| Lower Bollinger Band | 75.23 |
| Percent B (%b) | 0.31 |
| BandWidth | 20.50 |
| MACD Line | -2.60 |
| MACD Signal Line | -2.45 |
| MACD Histogram | -0.1521 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 86.50 | ||||
| Resistance 3 (R3) | 86.08 | 83.70 | 85.52 | ||
| Resistance 2 (R2) | 83.70 | 82.19 | 83.91 | 85.19 | |
| Resistance 1 (R1) | 82.15 | 81.27 | 82.92 | 82.57 | 84.87 |
| Pivot Point | 79.77 | 79.77 | 80.15 | 79.98 | 79.77 |
| Support 1 (S1) | 78.22 | 78.27 | 79.00 | 78.65 | 76.35 |
| Support 2 (S2) | 75.84 | 77.34 | 76.05 | 76.03 | |
| Support 3 (S3) | 74.29 | 75.84 | 75.70 | ||
| Support 4 (S4) | 74.72 |
